Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPX-100 as Adjunctive Therapy in Dravet Syndrome (ARGUS)
NCT04462770Phase 3Recruiting
- Sponsor
- Epygenix Therapeutics
- Start
- Sep 2020
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of clemizole in Dravet syndrome (3 arms), sponsored by Epygenix Therapeutics. Primary endpoints: Percent Change in Countable Motor Seizures Per 28 Days at 16 weeks and Percent Change in Countable Motor Seizures Per 28 Days in the Maintenance Period at 16 weeks. Started Sep 2020; status: recruiting.
02
Drugs
clemizole
03
Conditions
Dravet syndrome
Beyond the preview
Go deeper on NCT04462770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04462770.